Mergers with Future Rivals Can Boost Prices, Intensify Market Concentration, and Bar Entry

Rabbani, Maysam (2021): Mergers with Future Rivals Can Boost Prices, Intensify Market Concentration, and Bar Entry.

Abstract

In 2010, the Federal Trade Commission (FTC) stated that mergers between incumbents and future rivals may be anticompetitive. Lacking evidence, however, this statement was never used in litigation. This study empirically examines the statement. In 2012, an incumbent pharmaceutical firm acquired a promising future rival that was expected to enter competition within two years. First, I find strong evidence that, immediately after the merger, the incumbent boosted its existing drug prices. Second, the merger indirectly boosted the incumbent’s quantity of sales: higher drug prices increased the marginal returns on advertisement, and realizing that, the incumbent amplified its advertisement expenditures after the merger, and achieved a higher quantity of sales and market share. It explains how mergers with future rivals can increase market concentration by influencing advertisement. Third, mergers with future rivals can create strong entry barriers: by identifying and acquiring promising future rivals, incumbents can maintain their market dominance and postpone competition indefinitely. While mergers with future rivals are endemic to the pharmaceutical industry, I introduce a variation of it that explains the motive for major software industry mergers such as Facebook’s acquisition of Instagram and WhatsApp and Google’s takeover of Android and YouTube. Last, I propose an alternative merger analysis framework that suits mergers with future rivals.

• Item Type: MPRA Paper
• Language: English
• Keywords: pharmaceutical; entry barrier; merger; future rival; fringe firm
• Subjects: I - Health, Education, and Welfare > I1 - Health > I11 - Analysis of Health Care Markets; L - Industrial Organization > L4 - Antitrust Issues and Policies > L41 - Monopolization ; Horizontal Anticompetitive Practices; L - Industrial Organization > L5 - Regulation and Industrial Policy > L51 - Economics of Regulation

References

Anderson, L. (2021). FDA Drug Approval Process. accessed on June 20, 2021, Retrieved from https://www.drugs.com/fda-approval-process.html#:~:text=FDA\%20Approvals.\%20It\%20takes\%20on\%20average\%2012\%20years,\%28FDA\%29\%20to\%20begin\%20testing\%20the\%20drug\%20in\%20humans.

Arcidiacono, P., Ellickson, P. B., Landry, P., & Ridley, D. B. (2013). Pharmaceutical followers. International Journal of Industrial Organization, 31(5), 538-553.

Baker, L. C., Bundorf, M. K., & Kessler, D. P. (2020). Does multispecialty practice enhance physician market power? American Journal of Health Economics, 6(3), 324-347.

Barrenho, E., Miraldo, M., & Smith, P. C. (2019). Does global drug innovation correspond to burden of disease? The neglected diseases in developed and developing countries. Health economics, 28(1), 123-143. doi:10.1002/hec.3833

Bulik, B. S. (2020). AbbVie, Lilly and Gilead stay on top of pharma ad spending list for March amid steady overall spending. accessed on June 20, 2021, Retrieved from https://www.fiercepharma.com/marketing/abbvie-lilly-and-gilead-stay-top-pharma-ad-spending-list-for-march-amid-steady-overall

Bureau., U. S. C. (2014). Dataset: American Community Survey 1-Year Estimates (2010-2013).

Cabral, L. (2018). Standing on the shoulders of dwarfs: Dominant firms and innovation incentives. CEPR Discussion Paper.

Cabral, L. (2021). Merger policy in digital industries. Information Economics and Policy, 54, 100866. doi:10.1016/j.infoecopol.2020.100866

Calzolari, G., & Denicolò, V. (2021). Exploiting rivals' strengths. Available at SSRN 3781119.

Capps, C., Carlton, D., & David, G. (2020). Antitrust Treatment of Nonprofits: Should Hospitals Receive Special Care? Economic Inquiry. doi:10.1111/ecin.12881

CBS (Producer). (2017, June 20, 2021). “Pharma bro” Martin Shkreli remains defiant after guilty verdict June 20, 2021, Retrieved from https://www.youtube.com/watch?v=t43uTXBTJUA

CDC. (2019). HIV cost-effectiveness. accessed on June 20, 2021, Retrieved from https://www.cdc.gov/hiv/programresources/guidance/costeffectiveness/index.html}, journal={Centers for Disease Control and Prevention

Chorniy, A., Miller, D., & Tang, T. (2020). Mergers in Medicare Part D: Assessing market power, cost efficiencies, and bargaining power. International Journal of Industrial Organization, 68, 102548.

Cooper, Z., Gibbons, S., Jones, S., & McGuire, A. (2011). Does hospital competition save lives? Evidence from the English NHS patient choice reforms. The Economic Journal, 121(554), F228-F260. doi:10.1111/j.1468-0297.2011.02449.x

Cunningham, C., Ederer, F., & Ma, S. (2021). Killer acquisitions. Journal of Political Economy, 129(3), 649-702. doi:10.1086/712506

Duggan, M. (2000). Hospital Ownership and Public Medical Spending. The Quarterly Journal of Economics, 115(4). doi:10.1162/003355300555097

Forbes. (2017). Why Did That Drug Price Increase 6,000\%? It's The Law. accessed on June 20, 2021, Retrieved from https://www.forbes.com/sites/matthewherper/2017/02/10/a-6000-price-hike-should-give-drug-companies-a-disgusting-sense-of-deja-vu/?sh=404074f571f5

FTC. (2010). Horizontal merger guidelines: U.S. Dept. of Justice.

FTC. (2016a). Lupin Ltd., et al., In the Matter of. accessed on June 20, 2021, Retrieved from https://www.ftc.gov/enforcement/cases-proceedings/151-0202/lupin-ltd-et-al-matter

FTC. (2016b). Mylan, N.V., In the Matter of. accessed on June 20, 2021, Retrieved from https://www.ftc.gov/enforcement/cases-proceedings/161-0102/mylan-nv-matter

FTC. (2019). AbbVie Inc., et al. Federal Trade Commission, Plaintiff, v. AbbVie Inc.; Abbott Laboratories; Unimed Pharmaceuticals, LLC; Besins Healthcare, Inc.; and Teva Pharmaceuticals USA, Inc., Defendants. In: FTC.

FTC. (2020a). Facebook, Inc., FTC v. accessed on December 17, 2021, 2021, Retrieved from https://www.ftc.gov/enforcement/cases-proceedings/191-0134/facebook-inc-ftc-v

FTC. (2020b). FTC and NY Attorney General Charge Vyera Pharmaceuticals, Martin Shkreli, and Other Defendants with Anticompetitive Scheme to Protect a List-Price Increase of More Than 4,000 Percent for Life-Saving Drug Daraprim. In: FTC.

Gaynor, M., Ho, K., & Town, R. J. (2015). The industrial organization of health-care markets. Journal of Economic Literature, 53(2), 235-284. doi:10.1257/jel.53.2.235

Gaynor, M., & Vogt, W. B. (2003). Competition among hospitals. Retrieved from

Gilead. (2012). Gilead Sciences Completes Acquisition of Pharmasset, Inc. accessed on June 20, 2021, Retrieved from https://www.gilead.com/news-and-press/press-room/press-releases/2012/1/gilead-sciences-completes-acquisition-of-pharmasset-inc

Goodman-Bacon, A. (2021). Difference-in-differences with variation in treatment timing. Journal of Econometrics. doi:10.1016/j.jeconom.2021.03.014

Harrington, D. E., & Sayre, E. A. (2010). Managed care and measuring medical outcomes: did the rise of HMOs contribute to the fall in the autopsy rate? Social science & medicine, 70(2), 191-198. doi:10.1016/j.socscimed.2009.09.018

Ho, V., & Hamilton, B. H. (2000). Hospital mergers and acquisitions: does market consolidation harm patients? Journal of Health Economics, 19(5), 767-791. doi:10.1016/S0167-6296(00)00052-7

ITA. (2021). International Trade Administration. Software and information technology spotlight. accessed on June 20, 2021, Retrieved from https://www.selectusa.gov/software-and-information-technology-services-industry-united-states

Jackson, E. (2014). WhatsApp Could Be Worth $100 Billion Once It Monetizes Like Its Asian Peers. accessed on December 12, 2021, 2021, Retrieved from https://www.forbes.com/sites/ericjackson/2014/02/24/whatsapp-could-be-worth-100-billion-once-it-monetizes-like-its-asian-peers/?sh=76b582a53c98

Kemp, R. G. M., Kersten, N., & Severijnen, A. M. (2012). Price effects of dutch hospital mergers: an ex-post assessment of hip surgery. De Economist, 160(3), 237-255. doi:10.1007/s10645-012-9189-6

Kessler, D. P., & McClellan, M. B. (2000). Is hospital competition socially wasteful? The Quarterly Journal of Economics, 115(2), 577-615. doi:10.1162/003355300554863

Krauskopf, L. (2011). Gilead bets $11 billion on hepatitis in Pharmasset deal. accessed on June 20, 2021, Retrieved from https://www.reuters.com/article/us-gilead-pharmasset-idUSTRE7AK0XU20111121

Kuber, S. (2011). Pharmasset expands hepatitis C trial; shares rise. accessed on June 20, 2021, Retrieved from https://www.reuters.com/article/us-pharmassetinc/pharmasset-expands-hepatitis-c-trial-shares-rise-idUSTRE7993PD20111010

Lin, H., McCarthy, I. M., & Richards, M. (2021). Hospital Pricing Following Integration with Physician Practices. Journal of Health Economics, 77, 102444. doi:10.1016/j.jhealeco.2021.102444

MediaKix. (2017). How Much Is Instagram Worth Now? Over $100 Billion. accessed on June 20, 2021, Retrieved from https://mediakix.com/blog/how-much-is-instagram-worth-market-cap/

NCI. (2021). NCI Drug Dictionary. accessed on June 20, 2021, Retrieved from https://www.cancer.gov/publications/dictionaries/cancer-drug/def/clevudine

Ólafsdóttir, T., Ásgeirsdóttir, T. L., & Norton, E. C. (2017). Valuing pain using the subjective well-being method. Retrieved from

Ong, S. C., Mak, B., Aung, M. O., Li, S. C., & Lim, S. G. (2008). Health‐related quality of life in chronic hepatitis B patients. Hepatology, 47(4), 1108-1117. doi:10.1002/hep.22138

Ornaghi, C., Siotis, G., & Castanheira, M. (2019). Market definition in the pharmaceutical industry: a case of drugs hopping antitrust markets? CEPR DISCUSSION PAPER SERIES.

Picchi, A. (2019). Drug prices in 2019 are surging, with hikes at 5 times inflation. accessed on June 20, 2021, Retrieved from https://www.cbsnews.com/news/drug-prices-in-2019-are-surging-with-hikes-at-5-times-inflation/

Rabbani, M. (2021). Non-profit hospital mergers: the effect on healthcare costs and utilization. International Journal of Health Economics and Management, 1-29. doi:10.1007/s10754-021-09303-8

Rabideau, B., Eisenberg, M. D., Reid, R., & Sood, N. (2021). Effects of employer-offered high-deductible plans on low-value spending in the privately insured population. Journal of Health Economics, 76, 102424. doi:10.1016/j.jhealeco.2021.102424

SEC. (2021). EDGAR - GILD on NASDAQ. accessed on June 20, 2021, Retrieved from https://www.sec.gov/edgar/browse/?CIK=882095&owner=exclude

Shapiro, C. (2019). Protecting competition in the American economy: Merger control, tech titans, labor markets. Journal of Economic Perspectives, 33(3), 69-93. doi:10.1257/jep.33.3.69

Speights, K. (2020). What's the Outlook for Gilead Sciences?Speights. accessed on June 20, 2021, Retrieved from https://www.fool.com/investing/2020/06/21/whats-the-outlook-for-gilead-sciences.aspx

Staton, T. (2014). Riled by $84,000 Sovaldi, Senate panel digs into Gilead's Pharmasset buy. accessed on June 20, 2021, Retrieved from https://www.fiercepharma.com/m-a/riled-by-84-000-sovaldi-senate-panel-digs-into-gilead-s-pharmasset-buy

Strauss, D. (2019). Here's why one analyst thinks YouTube could be worth \$300 billion as a standalone company, making it more valuable than AT\&T, Exxon Mobil, and Bank of America (GOOGL). accessed on June 20, 2021, Retrieved from https://markets.businessinsider.com/news/stocks/youtube-value-as-separate-company-is-300-billion-analyst-says-2019-10-1028641059

Town, R., Wholey, D., Feldman, R., & Burns, L. R. (2006). The welfare consequences of hospital mergers. Retrieved from

TWR. (2021). Android Net Worth 2021, Wiki, Revenue, Founders. accessed on June 20, 2021, Retrieved from https://www.thewealthrecord.com/celebs-bio-wiki-salary-earnings-2019-2020-2021-2022-2023-2024-2025/other/android-net-worth/

Viscusi, W. K., Harrington Jr, J. E., & Sappington, D. E. (2018). Economics of regulation and antitrust: MIT press.

Watson, I. (2012). Dataset: Truven Health MarketScan Research Databases provided by Truven Health Analytics®, part of the IBM Watson Health™ business.

Wikipedia. (2021a). List of antiviral drugs. accessed on June 20, 2021, Retrieved from https://en.wikipedia.org/wiki/Listofantiviraldrugs

Wikipedia. (2021b). Pharmasset. accessed on June 20, 2021, Retrieved from https://en.wikipedia.org/wiki/Pharmasset

Wikipedia. (2021c). Sofobuvir. accessed on June 20, 2021, Retrieved from https://en.wikipedia.org/wiki/Sofosbuvir

Williams, S. (2017). The Scariest Prescription Drug Price Chart You'll Ever See. accessed on June 20, 2021, Retrieved from https://www.fool.com/investing/2017/04/23/the-scariest-prescription-drug-price-chart-youll-e.aspx

Williams, S. (2021). COVID-19 Vaccines: How Much Revenue Will Each Drugmaker Generate in 2021? accessed on, 2021, Retrieved from https://www.fool.com/investing/2021/07/13/covid-19-vaccines-how-much-revenue-in-2021/

Wollmann, T. G. (2019). Stealth consolidation: Evidence from an amendment to the Hart-Scott-Rodino Act. American Economic Review: Insights, 1(1), 77-94. doi:10.1257/aeri.20180137

Yang, B. M., Paik, S. W., Hahn, O. S., Yi, D. H., Choi, M. S., & Payne, S. (2001). Economic evaluation of the societal costs of hepatitis B in South Korea. Journal of gastroenterology and hepatology, 16(3), 301-308. doi:10.1046/j.1440-1746.2001.02443.x

Zeithaml, V. A., Bolton, R. N., Deighton, J., Keiningham, T. L., Lemon, K. N., & Petersen, J. A. (2006). Forward-looking focus: can firms have adaptive foresight? Journal of Service Research, 9(2), 168-183. doi:10.1177/1094670506293731